What’s wrong with the housing market?
NetScientific plc (LON:NSCI) recently announced full-year results for 2017. It was a year of progress for the company, which is carrying forward into 2018. In February 2018, ProAxsis had its first commercial sale of Neutrophil Elastase Airways Test (NEATstik) for measuring active neutrophil elastase, in this case to a research lab conducting a respiratory clinical trial with a pharmaceutical company. In March, Vortex announced a collaboration with BioView for automated clinical biomarker identification of circulating tumour cells.
First commercial sale of NEATstik
In February, ProAxsis announced the first commercial sale of NEATstik, a lateral flow device for rapid, easy monitoring of neutrophil elastase levels in the clinic or home from sputum samples. Neutrophil elastase is involved in chronic respiratory diseases such as cystic fibrosis and chronic obstructive pulmonary disease (COPD) and is an established biomarker of infection and inflammation.
Vortex collaboration with BioView
In March, Vortex announced a collaboration with BioView, an Israel-based company that provides automated cell imaging and analysis solutions. The purpose of this collaboration is to enable automated identification of clinical biomarkers expressed by circulating tumour cells that have been collected by Vortex’s platform.
To read the entire report Please click on the pdf File Below:
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
Which stock should you buy in your very next trade?
AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?
Unlock ProPicks AI